Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 3, 2009, Pages

  Guigoni, Céline ^a   Bezard, Erwan ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Abnormal involuntary movements; Dopamine D1 receptor; L dopa; Parkinson's disease; Sensitisation; Trafficking

Indexed keywords

ALPHA [AMINO(4 AMINOPHENYLTHIO)METHYLENE] 2 (TRIFLUOROMETHYL)PHENYLACETONITRILE; AMPA RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR KINASE 6; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LENTIVIRUS VECTOR; LEVODOPA; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEIN DARPP 32; RAS PROTEIN; RETINA S ANTIGEN; SIMVASTATIN; ST 198; UNCLASSIFIED DRUG;

ARTICLE; DRUG SPECIFICITY; DYSKINESIA; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; INTERNALIZATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PRENYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; VIRAL GENE THERAPY;

ANIMALS; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MODELS, BIOLOGICAL; PROTEIN TRANSPORT; RECEPTORS, DOPAMINE D1; SIGNAL TRANSDUCTION;

EID: 71849120030     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70783-7     Document Type: Article

References (31)

1. Cotzias G.C., Papavasiliou P.S., and Gellene R. Modification of Parkinsonism - chronic treatment with L-dopa. N Engl J Med 280 7 (1969) 337-345
2. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., Lanciego J.L., Artieda J., Gonzalo N., et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23 10 Suppl (2000) S8-19
3. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nat Rev Neurosci 2 (2001) 577-588
4. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9 9 (2008) 665-677
5. Alexander G.E., and Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13 (1990) 266-271
6. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
7. Nadjar A., Brotchie J.M., Guigoni C., Li Q., Zhou S.B., Wang G.J., et al. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. J Neurosci 26 34 (2006) 8653-8661
8. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57 1 (2005) 17-26
9. Corvol J.C., Muriel M.P., Valjent E., Feger J., Hanoun N., Girault J.A., et al. Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci 24 31 (2004) 7007-7014
10. Giorgi M., D'Angelo V., Esposito Z., Nuccetelli V., Sorge R., Martorana A., et al. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci 28 5 (2008) 941-950
11. Hossain M., and Weiner N. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease. J Pharmacol Exp Ther 267 3 (1993) 1105-1111
12. Cao X.B., Guan Q., Xu Y., Wang L., and Sun S.G. Mechanism of over-activation in direct pathway mediated by dopamine D(1) receptor in rats with levodopa-induced dyskinesia. Neurosci Bull 22 3 (2006) 159-164
13. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6 5 (2003) 501-506
14. Visanji N.P., Fox S.H., Johnston T., Reyes G., Millan M.J., and Brotchie J.M. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiol Dis 35 2 (2009) 184-192
15. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J.A., et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27 26 (2007) 6995-7005
16. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., and Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54 8 (2000) 1589-1595
17. Berthet A., Porras G., Doudnikoff E., Stark H., Cador M., Bezard E., et al. Pharmacological analysis demonstrates dramatic alteration of D1 Dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J Neurosci 29 15 (2009) 4829-4835
18. Guigoni C., Doudnikoff E., Li Q., Bloch B., and Bezard E. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis 26 2 (2007) 452-463
19. Bezard E., Gross C.E., Qin L., Gurevich V.V., Benovic J.L., and Gurevich E.V. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol Dis 18 2 (2005) 323-335
20. Bordet R., Ridray S., Schwartz J.C., and Sokoloff P. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12 6 (2000) 2117-2123
21. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9 6 (2003) 762-767
22. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., and Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94 7 (1997) 3363-3367
23. Gross C.E., Ravenscroft P., Dovero S., Jaber M., Bioulac B., and Bezard E. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. J Neurochem 84 6 (2003) 1246-1255
24. Fiorentini C., Busi C., Gorruso E., Gotti C., Spano P., and Missale C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74 1 (2008) 59-69
25. Marcellino D., Ferre S., Casado V., Cortes A., Le Foll B., Mazzola C., et al. Identification of dopamine D1-D3 receptor heteromers: Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 283 38 (2008) 26016-26025
26. Ahmed MR, Berthet A, Bychkov E, Li Q, Porras G, Bioulac BH, et al. Lentivirally-mediated overexpression of GRK6 alleviates L-DOPA-induced dyskinesia in experimental Parkinson's disease. In revision 2009.
27. Gerfen C.R., Miyachi S., Paletzki R., and Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22 12 (2002) 5042-5054
28. Pavon N., Martin A.B., Mendialdua A., and Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59 1 (2006) 64-74
29. Santini E., Alcacer C., Cacciatore S., Heiman M., Herve D., Greengarda P., et al. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 108 3 (2009) 621-633
30. Schuster S., Nadjar A., Guo J.T., Li Q., Ittrich C., Hengerer B., et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J Neurosci 28 17 (2008) 4311-4316
31. Gerfen C.R., Paletzki R., and Worley P. Differences between dorsal and ventral striatum in Drd1a dopamine receptor coupling of dopamine-and cAMP-regulated phosphoprotein-32 to activation of extracellular signal-regulated kinase. J Neurosci 28 28 (2008) 7113-7120